Zoetis Inc. reports developments as a global animal health company serving veterinarians, livestock producers and pet owners. Its updates center on medicines, vaccines, diagnostics, biopharmaceuticals and digital solutions for companion animals and livestock, organized commercially through U.S. and International segments.
Recurring news includes quarterly results and guidance, dividend declarations, investor conference presentations, pipeline and product-regulatory updates, and portfolio activity tied to animal health innovation. Company materials also describe R&D work across areas such as chronic kidney disease, oncology, cardiology, anxiety and obesity, as well as approved long-acting osteoarthritis pain products Lenivia and Portela.
Summary not available.
Zoetis Inc. (NYSE:ZTS) announced the acquisition of Basepaws, a petcare genetics company known for its genetic testing and health risk assessments for cats. This strategic move aims to enhance Zoetis’ precision animal health portfolio and R&D capabilities, leveraging Basepaws’ extensive genomic and microbiome databases. Financial details of the acquisition were not disclosed. The partnership is expected to boost innovation in petcare, improving health management and overall quality of care for pets.
Zoetis (NYSE:ZTS) will participate in the Stifel 2022 Jaws and Paws Conference on June 1, 2022, with Glenn David, Executive Vice President, presenting at 4:10 p.m. ET. Investors can access a live audio webcast of the presentation through the company's investor relations website, where a replay will also be available. Zoetis is a leading animal health company, generating $7.8 billion in revenue in 2021, focused on advancing animal care worldwide. The company operates in over 100 countries with a dedicated workforce of approximately 12,100 employees.
Zoetis Inc. (NYSE:ZTS) has declared a quarterly dividend of $0.325 per share, scheduled for payment on September 1, 2022. Shareholders on record as of July 21, 2022, will receive this dividend. Zoetis remains a leader in animal health, generating $7.8 billion in revenue in 2021 with a robust workforce of approximately 12,100 employees. The company emphasizes its commitment to advancing care for animals across over 100 countries.
Zoetis reported Q1 2022 revenue of $2.0 billion, up 6% year-over-year, and net income of $595 million, reflecting a 6% increase. Adjusted net income reached $625 million, or $1.32 per diluted share, representing a 4% rise. Operationally, revenue grew 9% and adjusted net income 8%, excluding foreign exchange impacts. The company updated its full-year revenue guidance to $8.225 - $8.375 billion primarily due to unfavorable foreign exchange rates. Despite uncertainties from global challenges, Zoetis remains confident in its operational growth.
The Zoetis Foundation announced a commitment of $4.9 million to support 20 initiatives across Africa, Brazil, China, Ukraine, and the U.S. The funds will enhance veterinary scholarships, diversity programming, and mental wellness, while also aiding livestock farmers and relief efforts in Ukraine. An initial donation of $150,000 has been made to the Red Cross, with a matching commitment of up to $150,000 for colleague donations. The Foundation aims to improve livelihoods, education, and mental health support for veterinarians and farmers, backed by an overall $35 million commitment through 2025.
Zoetis Inc (NYSE:ZTS) will host a webcast and conference call on May 5, 2022, at 8:30 a.m. (ET) to discuss its first quarter 2022 financial results. CEO Kristin Peck and CFO Wetteny Joseph will lead the call. Investors can access the live webcast via the Zoetis investor website. Zoetis, the world's leading animal health company, generated $7.8 billion in revenue in 2021 and employs approximately 12,100 people globally. More details and a replay of the call will be available on the website.
Zoetis (NYSE:ZTS) will attend the Barclays Global Healthcare Conference on March 17, 2022, where Wetteny Joseph, Executive Vice President and CFO, will present at 9:30 a.m. ET. Interested investors can access a live audio webcast of the presentation at http://investor.zoetis.com/events-presentations. A replay will be available on the Zoetis website afterward. Zoetis, a leading animal health company, generated $7.8 billion in revenue in 2021 and operates in over 100 countries.
Summary not available.
Zoetis (NYSE:ZTS) will participate in the Bank of America Securities 2022 Animal Health Summit on February 24, 2022. Wetteny Joseph, CFO, will present at 2:30 p.m. ET, answering questions from analysts. The event will be accessible via a live audio webcast, available at investor.zoetis.com/events-presentations, with a replay provided afterwards. Zoetis is a leader in animal health, generating $7.8 billion in revenue in 2021, with innovations in medicines and diagnostics serving over 100 countries.